The trial's principal investigators are Dr. The MASTER randomized trial will be carried out in 50 centers throughout Brazil, Canada, Czech Republic, France, Germany, Hungary, Israel, Poland and South Africa. I am confident that the successful completion of the MASTER Trial will be an important step towards making MGuard the standard of care in treatment of heart attack patients.” The importance of the MASTER Trial is validation of these results, in a large, randomized trial. CGuard EPS is an investigational device in USA The CGuard TM Embolic Prevention System (EPS) is a novel mesh carotid stent designed to improve patient safety through sustained embolic protection. Previous non-randomized trials have demonstrated the safety and efficacy of MGuard in heart attack patients. Eli Bar, CTO and Vice President of Research and Development of InspireMD, commented, “The enrollment of the first patient in the MASTER Trial is a significant milestone for InspireMD. Gregg Stone, Director of Cardiovascular Research and Education from Columbia University in New York, is the study chairman. Sub studies for cardiac MRI and invasive angiography are planned as well. CGuard EPS is an investigational device in USA The CGuard TM Embolic Prevention System (EPS) is a novel mesh carotid stent designed to improve patient safety through sustained embolic protection. Clinical follow-up will continue for one year and other important secondary endpoints such as TIMI flow, myocardial blush grade and MACE (major adverse cardiac events) rate will be measured. The primary endpoint is complete ST segment resolution. The MASTER Randomized Trial will enroll 432 patients in a two-arm, parallel design, with the objective to demonstrate superiority of the MGuard™ stent over commercially-approved bare-metal stents (BMS) or drug-eluting stents (DES) in achieving better myocardial reperfusion in primary angioplasty for the treatment of acute ST-elevation myocardial infarction (STEMI). Krystrof Żmudka, at the Krakow Specialist Hospital - John Paul II in Krakow, Poland. The patient was enrolled in the Department of Haemodynamics and Angiocardiography, headed by Dr. (“Inspire” or the “Company”), the developer of the MGuard™ mesh protective stent system, announced today that the first patient has been enrolled in the MASTER (MGuard for Acute ST Elevation Reperfusion) Randomized Trial, a multinational randomized controlled trial designed to demonstrate MGuard Coronary Stent’s superiority over standard care for STEMI (heart attack) patients. Gregg Stone from Columbia University, will enroll 432 patients (OTC BB: NSPR) (Inspire or the Company), the developer of the MGuard mesh protective stent system, today announced it has signed a distribution agreement with IMPLANTA, a well-established Moscow-based supplier to medical centers throughout the Russian Federation. It seems likely that stenting with the MGuard stent is feasible, however, its safety should be verified in larger studies.MASTER Trial, chaired by Dr. The results suggest that coronary stenting with a stent system containing a protection net to prevent coronarymicroembolization (eg the MGuard stent) in patients with acute coronary syndromes does not decrease procedural myocardial injury, as measured by TnI release. There was no statistically significant difference in median postprocedural TnI levels in either group. Two patients (one in each group) died during the hospital stay. A transient no-reflow phenomenon was observed in one interventional procedure in each group of patients (5% versus 4% NS). Technical success was 95% and 100% in the MGuard group and non-MGuard group, respectively. Serum concentrations of TnI were measured prior to, as well as 24 and 48 hours after, the PCI procedure. Forty-six acute coronarysyndrome patients referred for percutaneous coronary intervention (PCI) were included and randomized in this study. We hypothesized that this stent would partly eliminate distal embolization and decrease subsequent troponin I (TnI) release. The MGuard stent (InspireMD, Tel Aviv, Israel) was designed as a plaque/thrombus-trapping device, using a conventional bare metal stent covered with an ultrathin, flexible mesh net. This study was designed to determine whether the treatment of patients with unstable angina pectoris or non-Q-wave myocardial infarction with astent containing a protection net to prevent coronary microembolization affects the severity of biomarker release. Safety and Health Protection at Work and Fire Protection.Basic Literature & Teaching E-Resources.Guide for First-Year Students in General Medicine.Noteworthy Publications from our Faculty.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |